DRG Epidemiology's coverage of retinal vein occlusion comprises epidemiological estimates of key patient populations in the Mature Markets. We report the prevalence of retinal vein occlusion for each country as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 10 ten years for the other countries covered in this report. For the mature markets, the patient population is forecasted over a period of 20 twenty years.
DRG Epidemiology's retinal vein occlusion forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of retinal vein occlusion over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least 20 years of forecast data for the following retinal vein occlusion subpopulations:
- Total prevalent RVO cases by subtype scheme.
- Total prevalent RVO cases with comorbid macular edema.
- Mature Markets
- Key Findings
- Prevalence of Retinal Vein Occlusion per 100 People Aged 40 or Older in 2018 and 2038
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Retinal Vein Occlusion Over the Next 20 Years
- Analysis of the Prevalent Cases of Retinal Vein Occlusion in 2018 by Subtype Scheme
- Epidemiology Data
- Total Prevalent Cases of Retinal Vein Occlusion
- Total Prevalent Cases by Subtype Scheme
- Total Prevalent Cases with Comorbid Macular Edema
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Dr. Ravdeep Kaur, MPH; Alison Isherwood, MSc, MRes, PhD
Ravdeep Kaur started working in Decision Resources Inc. as an associate epidemiologist since December 31 st , 2015. She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. She holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from Rajiv Gandhi University of Health Sciences, India. She also has a Fellowship in Heath care Technology Assessment from World health Organization (WHO), India office. Prior to joining Decision Resources, Ravdeep worked as a Consultant in Reproductive, Maternal, Child and Adolescent Health Program in a United States Agency for International development (USAID) funded project.
Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.